IMCR
Immunocore Holdings Plc
A British biotechnology company that engineers a novel class of immunotherapies that harness the body's T cells to fight disease, using its ImmTAX platform. Its first approved medicine, KIMMTRAK, treats a rare eye cancer called uveal melanoma and was the first T-cell receptor therapy ever approved. The company grew out of T-cell research at the University of Oxford, spun out in 2008, and its platform name stands for "Immune Mobilizing Monoclonal TCRs Against X disease."
ADRUnderlying: IMCRCUSIP: 45258D105HealthcareGB1 holder
Immunocore Holdings plc Sponsored ADR
Total Value
$1.17M
Total Shares
36.7K
Net Share Change
+17.8K
Activity
1 buying
Investor
Value
Shares
Weight
Change
